These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 3258212

  • 1. Mechanisms of human CD5 modulation and capping induced by murine monoclonal antibody T101.
    Shawler DL, Johnson DE, McCallister TJ, Bartholomew RM, Dillman RO.
    Clin Immunol Immunopathol; 1988 May; 47(2):219-29. PubMed ID: 3258212
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma.
    Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, Neumann RD, Boland C, Perentesis P, Brown MR, Frincke JM, Lollo CP, Larson SM, Carrasquillo JA.
    Clin Cancer Res; 1998 Nov; 4(11):2691-700. PubMed ID: 9829731
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tissue distribution and serum kinetics of T101 monoclonal antibody during passive anti-cancer therapy.
    Shawler DL, Beauregard J, Halpern SE, Baird SM, Dillman RO.
    Clin Immunol Immunopathol; 1986 Oct; 41(1):43-54. PubMed ID: 3488861
    [Abstract] [Full Text] [Related]

  • 9. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia.
    Foon KA, Schroff RW, Bunn PA, Mayer D, Abrams PG, Fer M, Ochs J, Bottino GC, Sherwin SA, Carlo DJ.
    Blood; 1984 Nov; 64(5):1085-93. PubMed ID: 6333257
    [Abstract] [Full Text] [Related]

  • 10. Enhancing effects of monocytes on modulation of a lymphocyte membrane antigen.
    Schroff RW, Klein RA, Farrell MM, Stevenson HC.
    J Immunol; 1984 Oct; 133(4):2270-7. PubMed ID: 6236264
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody.
    Dillman RO, Shawler DL, Dillman JB, Royston I.
    J Clin Oncol; 1984 Aug; 2(8):881-91. PubMed ID: 6379121
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
    Derocq JM, Casellas P, Laurent G, Ravel S, Vidal H, Jansen F.
    J Immunol; 1988 Oct 15; 141(8):2837-43. PubMed ID: 3262669
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mathematical modeling for antibody therapy in the setting of antigenic modulation.
    Dillman RO, Koziol JA, Shawler DL.
    Mol Biother; 1988 Oct 15; 1(1):46-52. PubMed ID: 3267371
    [Abstract] [Full Text] [Related]

  • 18. Reactivity of Leu 1 and T101 monoclonal antibodies with B cell lymphomas (correlations with other immunological markers).
    Al Saati T, Laurent G, Caveriviere P, Rigal F, Delsol G.
    Clin Exp Immunol; 1984 Dec 15; 58(3):631-8. PubMed ID: 6239721
    [Abstract] [Full Text] [Related]

  • 19. Capping of human T cell specific determinants: kinetics of capping and receptor re-expression and regulation by the cytoskeleton.
    Kammer GM, Smith JA, Mitchell R.
    J Immunol; 1983 Jan 15; 130(1):38-44. PubMed ID: 6600189
    [No Abstract] [Full Text] [Related]

  • 20. CD5+B cells: differential capping and modulation of IgM and CD5.
    Jamin C, Lydyard PM, Le Corre R, Youinou PY.
    Scand J Immunol; 1996 Jan 15; 43(1):73-80. PubMed ID: 8560199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.